# Florian M.M. Baeres

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/florian-m-m-baeres/

## Facts

| Field | Value |
| --- | --- |
| Citations | 3,575 |
| Field | Diabetes Treatment and Management |
| h-index | 14 |
| i10-index | 18 |
| Last Known Institution | Novo Nordisk (Denmark) |
| OpenAlex ID | https://openalex.org/A5112384687 |
| Works | 40 |

## Researcher papers

- [Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes](https://scholariq.org/papers/effects-of-semaglutide-on-chronic-kidney-disease-in-patients-with-type-2/)
- [IL-6 inhibition with ziltivekimab in patients at high atherosclerotic risk (RESCUE): a double-blind, randomised, placebo-controlled, phase 2 trial](https://scholariq.org/papers/il-6-inhibition-with-ziltivekimab-in-patients-at-high-atherosclerotic-risk/)
- [The anatomy and innervation of the mammalian pineal gland](https://scholariq.org/papers/the-anatomy-and-innervation-of-the-mammalian-pineal-gland/)
- [The rationale, design and baseline data of FLOW, a kidney outcomes trial with once-weekly semaglutide in people with type 2 diabetes and chronic kidney disease](https://scholariq.org/papers/the-rationale-design-and-baseline-data-of-flow-a-kidney-outcomes-trial-with-once/)
- [Effects of Semaglutide on Heart Failure Outcomes in Diabetes and Chronic Kidney Disease in the FLOW Trial](https://scholariq.org/papers/effects-of-semaglutide-on-heart-failure-outcomes-in-diabetes-and-chronic-kidney/)
- [Effects of Liraglutide on Cardiovascular Outcomes in Patients With Diabetes With or Without Heart Failure](https://scholariq.org/papers/effects-of-liraglutide-on-cardiovascular-outcomes-in-patients-with-diabetes-with/)
- [LEADER 3—Lipase and Amylase Activity in Subjects With Type 2 Diabetes](https://scholariq.org/papers/leader-3-lipase-and-amylase-activity-in-subjects-with-type-2-diabetes/)
- [Comparison Of The Long-Term Effects Of Liraglutide And Glimepiride Monotherapy On Bone Mineral Density In Patients With Type 2 Diabetes](https://scholariq.org/papers/comparison-of-the-long-term-effects-of-liraglutide-and-glimepiride-monotherapy/)
- [LEADER 5: prevalence and cardiometabolic impact of obesity in cardiovascular high-risk patients with type 2 diabetes mellitus: baseline global data from the LEADER trial](https://scholariq.org/papers/leader-5-prevalence-and-cardiometabolic-impact-of-obesity-in-cardiovascular-high/)
- [Cardiovascular outcomes with semaglutide by severity of chronic kidney disease in type 2 diabetes: the FLOW trial](https://scholariq.org/papers/cardiovascular-outcomes-with-semaglutide-by-severity-of-chronic-kidney-disease/)
- [Kidney and Survival Benefits of Semaglutide in Diabetes With Chronic Kidney Disease](https://scholariq.org/papers/kidney-and-survival-benefits-of-semaglutide-in-diabetes-with-chronic-kidney/)

## Researcher topics

- [Diabetes Treatment and Management](https://scholariq.org/topics/diabetes-treatment-and-management/)
- [Chronic Kidney Disease and Diabetes](https://scholariq.org/topics/chronic-kidney-disease-and-diabetes/)
- [Diabetes Management and Research](https://scholariq.org/topics/diabetes-management-and-research/)
- [Diabetes, Cardiovascular Risks, and Lipoproteins](https://scholariq.org/topics/diabetes-cardiovascular-risks-and-lipoproteins/)
- [Heart Failure Treatment and Management](https://scholariq.org/topics/heart-failure-treatment-and-management/)

## Researcher university

- [Novo Nordisk (Denmark)](https://scholariq.org/institutions/novo-nordisk-denmark/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.